Summary of Study ST001135
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000760. The data can be accessed directly via it's Project DOI: 10.21228/M8FH6C This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST001135 |
Study Title | Different dose exposure of OPC-163493 on HepG2 cells (part-I) |
Study Type | Compound dosage test |
Study Summary | Metabolomics analysis were on 8 samples of HepG2 cells that were treated with compound OPC-163493 (DMSO control, 1, 3, or 10µM; each n=2) exposure for 30 min. |
Institute | Otsuka Pharmaceutical Co., Ltd. |
Last Name | Kanemoto |
First Name | Naohide |
Address | 463-10 Kagasuno Kawauchi-cho Tokushima 771-0192, Japan |
Kanemoto.Naohide@otsuka.jp | |
Phone | 81-03-6717-1400 |
Submit Date | 2019-02-07 |
Analysis Type Detail | LC-MS |
Release Date | 2019-03-06 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
Treatment ID: | TR001211 |
Treatment Summary: | HepG2 cells were seeded into a 100mm dish the day before OPC-163493 treatment. OPC-163493 treatments (DMSO control, 1, 3, or 10uM, each n=2) were performed for 30min in FBS-free DMEM with high glucose (25mM). |
Treatment Dose: | 0uM, 1uM, 3uM, 10uM |
Treatment Doseduration: | 30 min |
Cell Media: | MEM with Earle`s salts, L-Glutamine and Non-Essiontial Amino Acids, 10% fetal bovine serum, and 1mM sodium pyruvate solution |